Open AccessFIBROTIC CHANGES IN PATIENTS WITH CHRONIC HEART FAILURE WITH CARDIAC DYSSYNCHRONY AND ASSOCIATED TYPE 2 DIABETES MELLITUS
Author(s) -
T. A. Rudenko,
O V M O Bilchenko Khvysiuk,
O. Godlevska,
A P Braslavska
Publication year - 2018
Publication title -
the journal of v.n. karazin kharkiv national university. series "medicine"/the journal of v.n. karazin kharkiv national university. series "medicine"
Language(s) - English
Resource type - Journals
eISSN - 2313-6693
pISSN - 2313-2396
DOI - 10.26565/2313-6693-2018-35-08
Subject(s) - medicine , galectin 3 , heart failure , fibrosis , cardiology , diabetes mellitus , concomitant , type 2 diabetes mellitus , myocardial fibrosis , matrix metalloproteinase , ejection fraction , cardiac fibrosis , endocrinology
The study of fibrosis markers was carried out on 72 observed patients (mean age (69 ± 10.37) years) with chronic heart failure (CHF) of ischemic genesis with manifestations of cardiac dyssynchrony (CD) and concomitant type 2 diabetes mellitus – Galectin 3 and matrix metalloproteinase 1. All patients were divided into 2 groups, depending on the presence of CD. The CD was evaluated according to a conventional technique, the volume fraction of interstitial collagen was measured using the formula of J. Shirani and co-authors, the levels of Galectin-3 and matrix metalloproteinase 1 – by the enzyme-linked immunoassay according to the manufacturer's instructions. The data were processed using parametric and nonparametric statistics. It was revealed that the level of fibrosis development was higher in the group of patients with CD than in the group without CD. This indicates the dependence of the development of myocardial sites asynchronous reduction with the presence of interstitial collagen development. That further requires the study of the effect of anti-fibrotic, anti-ischemic and hypoglycemic agents on the progression of CD to prevent subsequent myocardial remodeling.